Palvella Therapeutics (PVLA) Net Cash Flow Growth (5y) (2018 - 2026)
Palvella Therapeutics (PVLA) Net Cash Flow Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.86 Bn | 1.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 128.29% |
| Dec 31, 2025 | -39.50% |
| Sep 30, 2025 | -18.89% |
| Jun 30, 2025 | -6.18% |
| Mar 31, 2025 | 11.54% |
| Dec 31, 2024 | 34.42% |
| Sep 30, 2024 | 53.13% |
| Jun 30, 2024 | 33.60% |
| Mar 31, 2024 | 19.00% |
| Dec 31, 2023 | 21.42% |
| Sep 30, 2023 | -18.10% |
| Jun 30, 2023 | 15.85% |
| Mar 31, 2023 | -58.22% |
| Dec 31, 2022 | 24.82% |
| Sep 30, 2022 | -15.80% |
| Jun 30, 2022 | -35.54% |
| Mar 31, 2022 | -26.90% |
| Dec 31, 2021 | 1.73% |
| Sep 30, 2021 | 30.93% |
| Jun 30, 2021 | 41.82% |